B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders

Patients with B-non-Hodgkin lymphoma (NHL) are at increased risk of morbidity and mortality from SARS-CoV-2. We investigated the relationship between B cell cytopenia and the SARS-CoV-2 vaccine response in B-NHL patients. We measured anti-RBD antibodies and the lymphocyte immunophenotype in 19 contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanguay, Mégane, Boutin, Marianne, Laumaea, Annemarie, Salaciak, Matthew, Mendoza, Alma, Cassis, Chantal, Ajjamada, Lissa, Assouline, Sarit, Patenaude, François, Clark, Michael Webster, Finzi, Andrés, Johnson, Nathalie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784616/
https://www.ncbi.nlm.nih.gov/pubmed/35105492
http://dx.doi.org/10.1016/j.vaccine.2022.01.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784616/
https://www.ncbi.nlm.nih.gov/pubmed/35105492
http://dx.doi.org/10.1016/j.vaccine.2022.01.040

Ejemplares similares